Comments on "Baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study".
作者信息
Li Rong, Wang JuanJuan, Li Qian, Guo QianYue, Zhao Jun Kang, Wei James Cheng-Chung, Zhang Li-Yun
机构信息
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
Shanxi Province Clinical Theranostics Technology Innovation Center for Immunologic and Rheumatic Diseases, Shanxi Province Clinical Research Center for Dermatologic and Immunologic Diseases (Rheumatic diseases), Taiyuan, China.
出版信息
Crit Care. 2024 Dec 20;28(1):428. doi: 10.1186/s13054-024-05187-5.
Abstract
摘要
相似文献
1
Comments on "Baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study".关于《巴瑞替尼与托珠单抗治疗新型冠状病毒肺炎机械通气患者的全国队列研究》的评论
Crit Care. 2024 Dec 20;28(1):428. doi: 10.1186/s13054-024-05187-5.
2
Commenting on baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study.关于巴瑞替尼与托珠单抗治疗新型冠状病毒肺炎机械通气患者的比较：一项全国性队列研究
Crit Care. 2024 Nov 5;28(1):357. doi: 10.1186/s13054-024-05116-6.
3
Baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study.巴瑞替尼与托珠单抗治疗新型冠状病毒肺炎机械通气患者的疗效比较：一项全国性队列研究
Crit Care. 2024 Aug 29;28(1):282. doi: 10.1186/s13054-024-05063-2.
4
Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study.托珠单抗与巴瑞替尼治疗新冠病毒肺炎合并低氧血症住院患者的疗效比较：一项多中心回顾性队列研究
Crit Care Explor. 2022 May 11;4(5):e0702. doi: 10.1097/CCE.0000000000000702. eCollection 2022 May.
5
Baricitinib versus tocilizumab in critically ill COVID-19 patients: A retrospective cohort study.巴瑞替尼对比托珠单抗治疗重症 COVID-19 患者：一项回顾性队列研究。
Pharmacotherapy. 2024 Jan;44(1):28-38. doi: 10.1002/phar.2867. Epub 2023 Aug 24.
6
Comparative Effectiveness of Baricitinib Versus Tocilizumab in Hospitalized Patients With COVID-19: A Retrospective Cohort Study of the National Covid Collaborative.巴瑞替尼与托珠单抗治疗新冠肺炎住院患者的疗效比较：一项全国新冠协作组的回顾性队列研究
Crit Care Med. 2025 Jan 1;53(1):e29-e41. doi: 10.1097/CCM.0000000000006444. Epub 2024 Oct 4.
7
Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19.巴瑞替尼与托珠单抗治疗中重度 COVID-19 的疗效比较。
Ann Pharmacother. 2023 Jul;57(7):769-775. doi: 10.1177/10600280221133376. Epub 2022 Oct 29.
8
Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study.托珠单抗与巴瑞替尼治疗 COVID-19 的疗效比较：一项回顾性队列研究。
Medicina (Kaunas). 2022 Apr 4;58(4):513. doi: 10.3390/medicina58040513.
9
Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis.托珠单抗、沙利鲁单抗和巴瑞替尼对 COVID-19 住院患者接受皮质类固醇治疗的死亡率的影响：系统评价和荟萃分析。
Clin Microbiol Infect. 2023 Jan;29(1):13-21. doi: 10.1016/j.cmi.2022.07.008. Epub 2022 Jul 19.
10
Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19.巴瑞替尼与托珠单抗治疗重症 COVID-19 的结局和不良反应。
Crit Care Med. 2023 Mar 1;51(3):337-346. doi: 10.1097/CCM.0000000000005756. Epub 2022 Dec 19.
引用本文的文献
1
Influence of SARS-CoV-2 variants and corticosteroid use on the effectiveness of baricitinib therapy in critical COVID-19.严重新型冠状病毒肺炎中，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体和皮质类固醇使用对巴瑞替尼治疗效果的影响
Crit Care. 2025 Mar 22;29(1):131. doi: 10.1186/s13054-025-05367-x.
本文引用的文献
1
Comparative Effectiveness of Baricitinib Versus Tocilizumab in Hospitalized Patients With COVID-19: A Retrospective Cohort Study of the National Covid Collaborative.巴瑞替尼与托珠单抗治疗新冠肺炎住院患者的疗效比较：一项全国新冠协作组的回顾性队列研究
Crit Care Med. 2025 Jan 1;53(1):e29-e41. doi: 10.1097/CCM.0000000000006444. Epub 2024 Oct 4.
2
Baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study.巴瑞替尼与托珠单抗治疗新型冠状病毒肺炎机械通气患者的疗效比较：一项全国性队列研究
Crit Care. 2024 Aug 29;28(1):282. doi: 10.1186/s13054-024-05063-2.
3
SARS-CoV-2 variant biology: immune escape, transmission and fitness.SARS-CoV-2 变体生物学：免疫逃逸、传播和适应性。
Nat Rev Microbiol. 2023 Mar;21(3):162-177. doi: 10.1038/s41579-022-00841-7. Epub 2023 Jan 18.
4
Acute and postacute sequelae associated with SARS-CoV-2 reinfection.与 SARS-CoV-2 再感染相关的急性和后期后遗症。
Nat Med. 2022 Nov;28(11):2398-2405. doi: 10.1038/s41591-022-02051-3. Epub 2022 Nov 10.
5
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.托珠单抗治疗 COVID-19 住院患者的疗效（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
6
Drug treatments for covid-19: living systematic review and network meta-analysis.Covid-19 的药物治疗：系统评价和网络荟萃分析。
BMJ. 2020 Jul 30;370:m2980. doi: 10.1136/bmj.m2980.
Zotero 插件